



European Framework Programmes


A Pharma Perspective

Ruth Keir

Executive Director

Worldwide Business Development

Patient and pharma are hit by the same issues



New approaches needed to keep innovation flowing to the patient



New approaches to develop innovation flow to the patient

- **Pre-competitive consortia becoming more common**
- **New ways to partner with external science developers in academia and biotech actively sought**
- **The Innovative Medicines Initiative key example**
 - **Joint Technology Initiative (JTI) under Framework 7**

Innovative Medicines Initiative


IMI



- Biggest public-private partnership in the area of medical research
- Innovative collaboration established between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) as a Joint Technology Initiative under FP7
- The objective is to make the drug discovery and development process more efficient to bring better medicines faster to patients, and to attract investment to Europe
- Support / Funding of research activities following open Calls and independent review



Financing of IMI Projects




Innovative Medicines Initiative


Founding Members EC and EFPIA



Key Engagement Stages



Key Engagement Stages




IMI Research Agenda

- **Predicting safety:** this addresses bottlenecks related to accurately evaluating the safety of a compound during the pre-clinical phase of the development process, but also impacts the later phases in clinical development.
- **Predicting efficacy:** this addresses bottlenecks in the ability to predict how a drug will interact in humans and how it may produce a change in function.
- **Knowledge management:** this addresses the more effective utilisation of information and data for predicting safety and efficacy.
- **Education and training:** this closes existing training gaps in the drug development process.


4 Pillars of IMI



Research Agenda



Key Engagement Stages




IMI Intellectual Property Policy


- Collective participation in research and collective access to the results
- Ownership of IP vests with the institution(s) where it was invented
- License to apply project IP to facilitate bringing new medicines to market
- Additional license to commercialise the IP itself may be negotiated
- Results must be made available to non-project participants
 - One year from project end, at the latest
 - Licences available to for fair and reasonable terms



IMI Intellectual Property Policy



Key Engagement Stages




Contribution in First Calls

Call Number		Pfizer Contribution	Other Pharma	EU
Call 3 - eTOX	Safety			
Call 5 - SAFE T	Safety			
Call 6 - PROTECT	Safety			
Call 9 - Europain	Efficacy			
Call 10 - NEWMEDS	Efficacy			
Call 12 - U-BIOPRED	Efficacy			
Call 13 - PROACTIVE	Efficacy			
Call 14 - EMTRAIN	Training			
Call 15 - SafeSci Met	Training			
Call 16 - Pharmatrain	Training			
Totals:				




IMI Stakeholder Partnerships



Hopes for FP8

- **Mechanisms to enable facile engagement with research aligned with scientific or policy challenges**
 - IMI took 5 years from inception to science getting off the ground
- **Improved understanding to enable cross sector collaboration**
 - Work to be done to align the diverse strategic objectives of multiple parties and EU
- **Improved ‘one stop shop’ advice at country level on Framework opportunities**

Thanks for your attention!



collaboration